GP Nord Ltd
Reg. Nr: 40203177406
Address: Kurzemes prospekts 23, Rīga, LV-1067, Latvija
On 19 September 2025, Riga hosted the forum “Medicines Distribution 2025: Challenges and Opportunities”, organized by the Industrial Pharmacists’ Section (RFS) of the Latvian Pharmacists’ Association. The event brought together industry professionals – responsible persons of wholesalers, company managers, board members, and specialists involved in quality supervision and the distribution of medicines in Latvia.
From GP Nord, the forum was attended by responsible persons Laura Saldovere and Lauma Salna. Both highlighted that such events are a great opportunity to hear the latest updates in one place, discover different approaches, and compare them with everyday practice.
Topics covered
The forum program was intensive and filled with practical insights. Key topics included:
- updates on the medicines verification system in Latvia,
- industry news presented by representatives of the State Agency of Medicines and the Health Inspectorate,
- outsourcing practices and supervision,
- risk management in distribution.
Particularly valuable were the real-life examples of how theoretical requirements are translated into practice – helping to see areas where improvements can still be made.
Takeaways for GP Nord
According to Laura and Lauma, the knowledge gained at the forum will be very useful in daily operations, including:
- a clearer understanding of current and upcoming regulatory requirements,
- ideas for improving quality supervision,
- a valuable perspective on risk management, which is becoming increasingly important to ensure a resilient supply chain.
Of course, meeting colleagues from across the sector in one place and exchanging thoughts in a more informal atmosphere was equally important – it helps to better understand how the industry as a whole is feeling today.
Looking ahead
At GP Nord, our main goal has always been to ensure the safe and timely availability of medicines to patients. Forums like this one provide a broader perspective – not only through our own experience but also by hearing the views and insights of others involved in these processes.
Looking back on the event, Laura Saldovere summed it up positively:
“The biggest benefit was realizing that we are all moving in the same direction. Everyone in that room wanted the same thing – for medicines to be available, high-quality, and safe for people.”
